Guilin Sanjin Pharmaceutical Co., Ltd.

002275

CNE100000DY9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
15.09 ^CNY	-0.79%		+1.48%	+4.14%

Mar. 04	Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Guilin Sanjin Pharma to Sell Land, Buildings For 111 Million Yuan	MT

Guilin Sanjin Pharmaceutical Co., Ltd. Announces the Profit Distribution Proposal for the Third Quarter of 2022

October 31, 2022 at 03:32 pm EDT

Guilin Sanjin Pharmaceutical Co., Ltd. announced on 31 October 2022 the profit distribution proposal for the third quarter of 2022 as follows: Cash dividend/10 shares (tax included) of CNY 4.00000000.

Latest news about Guilin Sanjin Pharmaceutical Co., Ltd.

Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04	CI
Guilin Sanjin Pharma to Sell Land, Buildings For 111 Million Yuan	Dec. 28	MT
Guilin Sanjin Pharmaceutical Co., Ltd. Implements Profit Distribution plan for the Third Quarter of 2023, Payable on 27 November 2023	Nov. 21	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves 2023 Third Quarter Profit Distribution Plan	Nov. 15	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Third Quarter Dividend for 2023	23-10-30	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Guilin Sanjin Pharmaceutical Co., Ltd.(XSEC:002275) added to S&P Global BMI Index	23-09-18	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 31, 2023	23-05-24	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Cash Dividend for 2022	23-05-22	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Board Elections	22-12-27	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Dividend for the Third Quarter of 2022	22-11-15	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Announces the Profit Distribution Proposal for the Third Quarter of 2022	22-10-31	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Biocytogen Pharmaceuticals Raises $60 Million in RemeGen-Backed Hong Kong IPO	22-08-31	MT
Biocytogen Pharmaceuticals Launches $70 Million Hong Kong IPO	22-08-19	MT
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-18	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021, Payable on 30 May 2022	22-05-24	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021	22-05-19	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2021	22-04-27	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-24	CI
Guilin Sanjin Pharmaceutical Co., Ltd.(XSEC:002275) dropped from S&P Global BMI Index	21-12-20	CI

Chart Guilin Sanjin Pharmaceutical Co., Ltd.

Duration

Period

Chart Guilin Sanjin Pharmaceutical Co., Ltd.

More charts

Company Profile

Guilin Sanjin Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research, production and distribution of Chinese patent medicines, as well as distribution of products. The Company's main products portfolio consists of watermelon frost series, including watermelon frost lozenge, guilin watermelon frost and watermelon frost throat lozenge, mainly used for treatment of throat and mouth diseases; sanjin tablets, mainly used for treatment of urinary system infection, as well as naomaitai capsules, mainly used for treatment of cardiovascular and cerebrovascular diseases. It distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.09

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
GUILIN SANJIN PHARMACEUTICAL CO., LTD.	+4.14%	1.23B
DONG-E-E-JIAO CO.,LTD.	+38.08%	6.01B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-16.43%	4.47B
TASLY PHARMACEUTICAL GROUP CO., LTD	-12.46%	3.11B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-0.21%	3.01B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-0.59%	2.6B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+34.54%	1.85B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.93%	1.66B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-10.63%	1.63B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.50%	1.53B

Alternative Medicine